연구용
제품 번호S7024
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| H9c2 | Function Assay | 10 μM | 4 h | reverses the effects of IL-27 | 26339633 | |
| NPC | Function Assay | 0-7.5 µM | abolishes EMT-like molecular alterations, and cell migration and invasion induced by RKIP knockdown | 25915430 | ||
| HASMC | Function Assay | 1.25-5 μM | 20 min | DMSO | inhibits p-(Y)-STAT-1,3,5 signals | 25849622 |
| H9c2 | Function Assay | 2/10 μM | 2 h | DMSO | abrogates the cytoprotective effects of IL-27 against SH | 25820907 |
| A431 | Growth Inhibition Assay | 2 μM | 2 h | blocks EGF-reversed decreases in cell viability | 25720435 | |
| A431 | Growth Inhibition Assay | 2 μM | 2 h | increases in apoptosis induced by shikonin | 25720435 | |
| SiHa | Cell Viability Assay | 5-75 nM | 24 h | shows morphology of a typical apoptotic cell and dose-dependent loss of cell viability | 25539644 | |
| SiHa | Function Assay | 5-75 nM | 24 h | reduces the phosphorylation at the tyrosine residue 705 | 25539644 | |
| ECA109 | Growth Inhibition Assay | 0-20 μM | 24 h | IC50=5.50 μM | 25492480 | |
| TE13 | Growth Inhibition Assay | 0-20 μM | 24 h | IC50=6.15 μM | 25492480 | |
| KYSE150 | Growth Inhibition Assay | 0-20 μM | 24 h | IC50=12.64 μM | 25492480 | |
| ECA109 | Clonogenic Survival Assay | 0.5 μM | 24 h | suppresses the clonogenic formation | 25492480 | |
| TE13 | Clonogenic Survival Assay | 0.5 μM | 24 h | suppresses the clonogenic formation | 25492480 | |
| KYSE150 | Clonogenic Survival Assay | 0.5 μM | 24 h | suppresses the clonogenic formation | 25492480 | |
| ECA109 | Function Assay | 0.5 μM | 24 h | enhances IR-induced generation of DSBs | 25492480 | |
| PC3M-1E8 | Function Assay | 2.5/5/10 μM | 0-4 h | inhibits the STAT3 activation in a dose- and time-dependent manner | 25261365 | |
| PC3M-1E8 | Function Assay | 10 μM | 24 h | downregulates Bcl-xL, survivin and c-Myc | 25261365 | |
| PC3M-1E8 | Function Assay | 10 μM | 24 h | inhibits IL-6 induced STAT3 activation and the IL-6-induced STAT3 activation | 25261365 | |
| PC3M-1E8 | Clonogenic Survival Assay | 2.5/5/10 μM | inhibits the colony formation significantly | 25261365 | ||
| MDA-MB-231 | Function Assay | 20 μM | 2 h | exhibits Snail and E-cadherin expression | 25153349 | |
| H9c2 | Function Assay | 20 µM | 30 min | DMSO | abolishes propofol-induced AKT phosphorylation at both ser473 and thr308 | 25105067 |
| HaCaT | Growth Inhibition Assay | 10 µM | 20 min | DMSO | enhances sorafenib- and sunitinib-induced growth inhibition | 25013907 |
| Caki-1 | Growth Inhibition Assay | 10 µM | 20 min | DMSO | enhances sorafenib- and sunitinib-induced growth inhibition | 25013907 |
| HaCaT | Apoptosis Assay | 10 µM | 20 min | DMSO | increases proportions of apoptotic cells due to treatment with sorafenib or sunitinib | 25013907 |
| FHL-primed hNSCs | Cell Viability Assay | 0.02-5 μM | 72 h | leads to the loss of cell viability at high concentration | 24945434 | |
| ELL-primed hNSCs | Cell Viability Assay | 0.02-5 μM | 72 h | leads to the loss of cell viability at high concentration | 24945434 | |
| SS | Cell Viability Assay | 1-10 μM | 72 h | DMSO | causes a dose-dependent inhibition of the viability | 24756111 |
| SeAx | Cell Viability Assay | 1-10 μM | 72 h | DMSO | causes a dose-dependent inhibition of the viability | 24756111 |
| HuT-78 | Cell Viability Assay | 1-10 μM | 72 h | DMSO | causes a dose-dependent inhibition of the viability | 24756111 |
| CD4+ | Apoptosis Assay | 10 μm | 24 h | DMSO | induces apoptosis strongly | 24756111 |
| MCF-7 | Growth Inhibition Assay | 0.469-3.75 μM | 5 d | reduces cell number significantly | 24728078 | |
| MCF-7/LCC1 | Growth Inhibition Assay | 0.469-3.75 μM | 5 d | reduces cell number significantly | 24728078 | |
| MCF-7/LCC9 | Growth Inhibition Assay | 0.469-3.75 μM | 5 d | reduces cell number significantly | 24728078 | |
| HaCaT | Growth Inhibition Assay | 10 µM | 20 min | DMSO | enhances everolimus-induced cell growth inhibition | 24423131 |
| HaCaT | Apoptosis Assay | 10 µM | 20 min | DMSO | enhances the apoptotic effects of everolimus | 24423131 |
| MDA-MB-231 | Function Assay | 10 µM | 24 h | DMSO | reduces P-STAT3 expression | 24376586 |
| SUM-159 | Function Assay | 10 µM | 24 h | DMSO | reduces P-STAT3 expression | 24376586 |
| SK-BR-3 | Function Assay | 10 µM | 24 h | DMSO | reduces P-STAT3 expression | 24376586 |
| MCF7-HER2 | Growth Inhibition Assay | 0-10 μM | 48 h | DMSO | induces cell death dose dependently | 24297508 |
| MCF7-HER2 | Function Assay | 5 μM | 24 h | DMSO | diminishes Sox-2, Oct-4, and slug expression | 24297508 |
| MCF7-HER2 | Function Assay | 5 μM | 24 h | DMSO | decreases the expression levels of EMT markers, vimentin and slug | 24297508 |
| MCF7-HER2 | Growth Inhibition Assay | 5 μM | 24 h | DMSO | enhances cell growth inhibition combined with Herceptin | 24297508 |
| HMECs | Function Assay | 10 μM | 2 h | inhibits IFNα mediated phosphorylation of STAT1, STAT2 and STAT3 | 24211327 | |
| HTR8/SVneo | Function Assay | 1 μM | 1 h | suppressed OSM-induced STAT3 phosphorylation | 24060241 | |
| HTR8/SVneo | Function Assay | 0.5/1 μM | 48 h | restores the expression of E-cadherin suppressed by OSM | 24060241 | |
| HTR8/SVneo | Function Assay | 1 μM | 48 h | significantly increases migration by OSM | 24060241 | |
| C13* | Apoptosis Assay | 0-10 μM | 24/48 h | induces apoptosis in a dose and time dependent manner | 23962558 | |
| OV2008 | Apoptosis Assay | 0-10 μM | 24/48 h | induces apoptosis in a dose and time dependent manner | 23962558 | |
| C13* | Apoptosis Assay | 24/48 h | enhances cisplatin-induced apoptosis | 23962558 | ||
| OV2008 | Apoptosis Assay | 24/48 h | enhances cisplatin-induced apoptosis | 23962558 | ||
| W480 | Function Assay | 2.5/10 μM | 30 min | DMSO | sensitizes cells to chemoradiotherapy in a dose-dependent manner | 23934972 |
| SW837 | Function Assay | 2.5/10 μM | 30 min | DMSO | sensitizes cells to chemoradiotherapy in a dose-dependent manner | 23934972 |
| T24 | Function Assay | 2/10/20 μM | 24 h | causes dose-dependent inhibition of the CXCL12-induced increase of invading cells | 23526079 | |
| CNE1 | Function Assay | 20 µM | 48 h | blocks the IL-6 increased phosphorylation of Stat3 | 23382914 | |
| CNE2 | Function Assay | 20 µM | 48 h | blocks the IL-6 increased phosphorylation of Stat3 | 23382914 | |
| HONE1 | Function Assay | 20 µM | 48 h | blocks the IL-6 increased phosphorylation of Stat3 | 23382914 | |
| CNE1 | Growth Inhibition Assay | 4 μM | significantly reduces cell viability | 23382914 | ||
| CNE1 | Function Assay | 0-20 μM | 0-4 h | inhibits Stat3 activation in a dose- and time-dependent manner | 23382914 | |
| CNE2 | Function Assay | 0-20 μM | 0-4 h | inhibits Stat3 activation in a dose- and time-dependent manner | 23382914 | |
| HONE1 | Function Assay | 0-20 μM | 0-4 h | inhibits Stat3 activation in a dose- and time-dependent manner | 23382914 | |
| CNE1 | Cell Viability Assay | 0.5-64 μM | 48 h | suppresses cell viability in a dose- and time-dependent manner | 23382914 | |
| CNE2 | Cell Viability Assay | 0.5-64 μM | 48 h | suppresses cell viability in a dose- and time-dependent manner | 23382914 | |
| HONE1 | Cell Viability Assay | 0.5-64 μM | 48 h | suppresses cell viability in a dose- and time-dependent manner | 23382914 | |
| C666-1 | Cell Viability Assay | 0.5-64 μM | 48 h | suppresses cell viability in a dose- and time-dependent manner | 23382914 | |
| CNE1 | Apoptosis Assay | 10 µM | 48 h | induces apoptosis | 23382914 | |
| CNE2 | Apoptosis Assay | 10 µM | 48 h | induces apoptosis | 23382914 | |
| HONE1 | Apoptosis Assay | 10 µM | 48 h | induces apoptosis | 23382914 | |
| CNE2 | Cell Viability Assay | 1/2 μM | 48 h | sensitize cells to radiotherapy | 23382914 | |
| HONE1 | Cell Viability Assay | 1/2 μM | 48 h | sensitize cells to radiotherapy | 23382914 | |
| C666-1 | Cell Viability Assay | 1/2 μM | 48 h | sensitize cells to radiotherapy | 23382914 | |
| HEC-1A | Function Assay | 1 μM | 24 h | DMSO | blocks the MUC20-enhanced invasion triggered by 10% FBS | 23262208 |
| RL95-2 | Function Assay | 1 μM | 24 h | DMSO | blocks the MUC20-enhanced invasion triggered by 10% FBS | 23262208 |
| HEC-1A | Function Assay | 1 μM | 24 h | DMSO | blocks the MUC20-enhanced invasion triggered by EGF | 23262208 |
| RL95-2 | Function Assay | 1 μM | 24 h | DMSO | blocks the MUC20-enhanced invasion triggered by EGF | 23262208 |
| CT26 | Function Assay | 20 mM | 1 h | suppresses HGF-induced VEGF expression | 23233163 | |
| UM-SCC-17B | Growth Inhibition Assay | IC50=2.562 ± 0.409 μM, GI50=1.279 ± 0.194 μM | 22770899 | |||
| OSC-19 | Growth Inhibition Assay | IC50=3.481 ± 0.953 μM, GI50=1.366 ± 0.770 μM | 22770899 | |||
| Cal33 | Growth Inhibition Assay | IC50=2.282 ± 0.423 μM, GI50=1.349 ± 0.363 μM | 22770899 | |||
| UM-SCC-22B | Growth Inhibition Assay | IC50=2.648 ± 0.542 μM, GI50=1.320 ± 0.204 μM | 22770899 | |||
| UM-SCC-17B | Function Assay | 0-30 μM | 0-24 h | inhibits STAT3 activation dose and time dependently | 22770899 | |
| OSC-19 | Function Assay | 0-30 μM | 0-24 h | inhibits STAT3 activation dose and time dependently | 22770899 | |
| Cal33 | Function Assay | 0-30 μM | 0-24 h | inhibits STAT3 activation dose and time dependently | 22770899 | |
| UM-SCC-22B | Function Assay | 0-30 μM | 0-24 h | inhibits STAT3 activation dose and time dependently | 22770899 | |
| U-87MG | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| U-373MG | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| SH-SY5Y | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| Tu-9648 | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| Neuro-2a | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| PCNs | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| PGCs | Cell Viability Assay | 0-10 μM | 72 h | DMSO | inhibits cell viability dose dependently | 25436682 |
| RAW264.7 | Function Assay | 10 μM | 12 h | abrogates the mRNA expressions of JAK2, STAT1, STAT2, and STAT3 induced by DON and T-2 toxin | 22454431 | |
| RAW264.7 | Apoptosis Assay | 5/10 μM | 45 min | enhances toxins induced apoptosis and MMP loss | 22454431 | |
| SW480 | Cell Viability Assay | 5/10/20 μM | 72 h | inhibits cell viability of the ALDH+/CD133+ cells | 21900397 | |
| HCT116 | Cell Viability Assay | 5/10/20 μM | 72 h | inhibits cell viability of the ALDH+/CD133+ cells | 21900397 | |
| DLD-1 | Cell Viability Assay | 5/10/20 μM | 72 h | inhibits cell viability of the ALDH+/CD133+ cells | 21900397 | |
| SNU387 | Cell Viability Assay | 20 μM | 24 h | reduces cell viability | 21311975 | |
| SNU398 | Cell Viability Assay | 20 μM | 24 h | reduces cell viability | 21311975 | |
| HepG2 | Cell Viability Assay | 20 μM | 24 h | reduces cell viability | 21311975 | |
| Huh-7 | Cell Viability Assay | 20 μM | 24 h | reduces cell viability | 21311975 | |
| VSMC | Growth Inhibition Assay | 3/5/10 μM | 30 min | DMSO | prevents PDGF- and thrombin-mediated VSMC proliferation in a dose-dependent manner | 20847306 |
| MDA-MB-231 | Apoptosis Assay | 10 μM | 24 h | DMSO | induces apoptosis | 17114005 |
| MDA-MB-435S | Apoptosis Assay | 10 μM | 24 h | DMSO | induces apoptosis | 17114005 |
| AsPC1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay, IC50 = 1.32 μM. | 24904966 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against ER-negative and triple-negative human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay, IC50 = 2.89 μM. | 24904966 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against ER-positive human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay, IC50 = 3.6 μM. | 24904966 | ||
| PANC1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay, IC50 = 3.77 μM. | 24904966 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50 = 1.56 μM. | 26396689 | ||
| MDA-MB-435S | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 48 hrs by MTT assay, IC50 = 1.87 μM. | 26396689 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50 = 2.16 μM. | 26396689 | ||
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50 = 2.5 μM. | 26396689 | ||
| DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50 = 2.5 μM. | 26396689 | ||
| PANC1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50 = 2.9 μM. | 26396689 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 1.08 μM. | 27718470 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 1.68 μM. | 27718470 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 2.36 μM. | 27718470 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 4.4 μM. | 27718470 | ||
| AD293 | Function assay | 6 hrs | Inhibition of IFNgamma-stimulated GFP/FLAG-tagged STAT3 dimerization in human AD293 cells incubated for 6 hrs by Western blot analysis, IC50 = 5.1 μM. | 30228000 | ||
| MDA-MB-231 | Function assay | 1 to 10 uM | 12 hrs | Inhibition of STAT3 phosphorylation at Tyr705 in human MDA-MB-231 cells at 1 to 10 uM after 12 hrs by western blot analysis | 24904966 | |
| MDA-MB-231 | Anticancer assay | 1 to 10 uM | 48 hrs | Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition, apoptosis and cellular morphological changes at 1 to 10 uM after 48 hrs by light microscopy | 24904966 | |
| MDA-MB-231 | Function assay | 1 to 10 uM | 12 hrs | Decrease in STAT3 protein expression in human MDA-MB-231 cells at 1 to 10 uM after 12 hrs by western blot analysis | 24904966 | |
| MCF7 | Function assay | 12 hrs | Inhibition of STAT3 phosphorylation at Y705 in human MCF7 cells after 12 hrs by Western blot analysis | 26396689 | ||
| MDA-MB-435S | Function assay | 12 hrs | Inhibition of STAT3 phosphorylation at Y705 in human MDA-MB-435S cells after 12 hrs by Western blot analysis | 26396689 | ||
| MDA-MB-231 | Function assay | 12 hrs | Inhibition of STAT3 phosphorylation at Y705 in human MDA-MB-231 cells after 12 hrs by Western blot analysis | 26396689 | ||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 211.19 | 화학식 | C8H5NO4S |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 19983-44-9 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | N/A | Smiles | C1=CC(=CC2=C1C=CS2(=O)=O)[N+](=O)[O-] | ||
|
In vitro |
DMSO
: 42 mg/mL
(198.87 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| 특징 |
Stattic is the first non-peptide small molecule with inhibitory activity against STAT3 SH2 domain regardless of the STAT3 phosphorylation state in vitro.
|
|---|---|
| Targets/IC50/Ki |
STAT3
(Cell-free assay) 5.1 μM
|
| 시험관 내(In vitro) |
Stattic은 gp130 수용체에서 유래한 포스포티로신 함유 펩타이드가 STAT3 SH2 도메인에 결합하는 것을 강력한 온도 의존적인 방식으로 억제한다. 이 화합물은 티로신 인산화된 펩타이드가 티로신 키나아제 Lck의 SH2 도메인에 결합하는 데 매우 약한 영향만을 미친다. 그리고 다른 두 가지 이량체 전사 인자(c-Myc/Max 및 Jun/Jun)의 이량체화를 억제하지 않는다. 또한 플루오레세인 표지된 포스포펩타이드가 STAT1 및 STAT5b의 SH2 도메인에 결합하는 것을 억제한다. 이 화학물질은 10 μM 농도에서 STAT3 동종이량체의 DNA 결합을 선택적으로 억제한다. STAT3의 Tyr705에서의 세포 인산화를 억제하는 것으로 나타났으며, STAT1의 Tyr701에서의 인산화(HepG2 세포에서) 또는 JAK1, JAK2 및 c-Src의 인산화(MDA-MB-231 및 MDA-MB-235S 세포에서)에는 거의 영향을 미치지 않는다. 이 화합물은 STAT3 의존성 유방암 세포주의 아팝토시스 비율을 증가시킨다. |
| 키나아제 분석 |
고속 스크리닝 및 형광 편광 분석
|
|
스크리닝은 약 30 °C에서 수행됩니다. 스크리닝 히트의 특이성은 STAT1, STAT5 및 Lck의 SH2 도메인에 대한 시험 화합물의 결합에 대한 유사 분석에서 검증됩니다. 모든 FP 분석에 사용되는 완충액 성분의 최종 농도는 10 mM HEPES (pH 7.5), 1 mM EDTA, 0.1% Nonidet P-40, 50 mM NaCl 및 10% DMSO입니다. Dithiothreitol의 부재는 억제 활성에 필수적입니다. 펩타이드 서열은 다음과 같습니다: STAT3, 5-carboxyfluorescein-GY(PO3H2)LPQTV-NH2; STAT1, 5-carboxyfluorescein-GY(PO3H2)DKPHVL; STAT5, 5-carboxyfluorescein-GY(PO3H2)LVLDKW; 및 Lck, 5-carboxyfluorescein-GY(PO3H2)EEIP. 30 °C에서의 특이성 분석을 위해 단백질은 150 nM (STAT1, STAT3 및 STAT5)으로 사용됩니다. 37 °C에서의 특이성 분석을 위해 단백질은 370 nM (STAT3) 또는 100 nM (Lck)으로 사용됩니다. 단백질은 에펜도르프 튜브에서 시험 화합물과 지정된 온도에서 60분 동안 배양한 후 해당 5-카르복시플루오레세인 표지된 펩타이드를 첨가합니다 (최종 농도: 10 nM). 실온에서 측정하기 전에 혼합물은 최소 30분 동안 평형을 이루도록 합니다. 시험 화합물은 DMSO에 20배 희석된 재고 용액에서 지정된 농도로 사용됩니다. 결합 곡선 및 억제 곡선은 SigmaPlot으로 피팅됩니다. 모든 경쟁 곡선은 독립적인 실험에서 세 번 반복됩니다.
|
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | p-STAT3 / STAT3 Survivin / c-Myc / Bcl-xl PARP / C-PARP / Caspase-3 / C-Caspse-3 |
|
25261365 |
| Immunofluorescence | p-STAT3 / STAT3 / Survivin |
|
25261365 |
| Growth inhibition assay | Cell viability |
|
23382914 |
| ELISA | BDNF |
|
27456333 |